We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tyratech (DI) | LSE:TYRU | London | Ordinary Share | COM SHS USD0.001 (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMTYR TIDMTYRU
RNS Number : 7961P
TyraTech, Inc.
23 February 2016
For release at 07.00: 23 February 2016
TyraTech, Inc.
("TyraTech" or the "Company")
New Distribution Agreement with major US retailer: Rite Aid
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences technology company focused on nature-derived insect and parasite control products, announces a new distribution agreement for its award winning head lice treatment Vamousse(R) with major US retailer Rite Aid Corporation ("Rite Aid").
Rite Aid is a Fortune 500 company and drugstore chain in the United States with over 4,500 stores nationwide. With the addition of Rite Aid, Vamousse is now available in all of the top four retail pharmacy chains in the US and nationwide can be found in a total of over 24,000 individual stores, including Walmart, Walgreens, and CVS Health.
TyraTech has also made progress in increasing Vamousse's UK presence having increased its store presence in Tesco and Sainsbury's to achieve coverage of more than 7,800 retail stores.
Bruno Jactel, Chief Executive Officer, said: "We recognize that the purchase of head lice treatment is for almost all parents and caregivers an emergency buy. When a child is identified with a lice infestation, you want to find a resolution immediately. For this reason, achieving strong and comprehensive distribution in our major target markets is paramount. Our strategy has been to make sure that the consumer can find our product in whatever store is closest to home and then to drive brand awareness through our marketing programs. Broad distribution helps us achieve the best return on investment for our marketing spend.
"We continue to build on the success of establishing the Vamousse head lice franchise and monetizing our technology. These additional distribution agreements across major retailers in both the US and UK are strong validation for the value and efficacy of our products for consumers and retailers alike."
*-ends*-
For further information please visit: www.tyratech.com or contact:
TyraTech Inc. Tel: +1 919 415 4340 Bruno Jactel, Chief Executive Officer Tel: +1 919 415 4287 Erica H. Boisvert, Chief Financial Officer SPARK Advisory Partners Limited, Nominated Adviser Tel: +44 203 368 3551 Matt Davis / Mark Brady Allenby Capital Limited, Joint Broker Tel: +44 20 3328 5656 Chris Crawford Whitman Howard Limited, Joint Broker Tel: +44 20 7659 1234 Ranald McGregor-Smith/ Niall Devins Belvedere Communications (PR) Tel: +44 20 3567 0510 John West / Kim van Beeck:
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRSESFWEFMSEEE
(END) Dow Jones Newswires
February 23, 2016 02:00 ET (07:00 GMT)
1 Year Tyratech (DI) Chart |
1 Month Tyratech (DI) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
